HIPEC addition to SCS did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer patients. Both SCS alone and SCS with HIPEC groups exhibited similar safety profiles, ...
Obesity is associated with increased surgical complications in EOC, including wound infections and intestinal problems, but not with overall survival differences. Meta-analysis showed obesity linked ...
JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials. This is an ASCO Meeting ...
Bevacizumab addition to chemotherapy showed significant progression-free survival benefits in high-risk epithelial ovarian cancer patients but not in overall survival. The BEV1L study used real-world ...
Long-term survival analysis of a randomized phase II study of front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002) ...
Ovarian cancer remains the deadliest gynecologic cancer, largely because it is rarely found early. Symptoms are often vague, ...
Ovarian cystic neoplasms are ovarian tumors that have cyst-like qualities. They can include epithelial ovarian tumors and germ cell tumors called teratomas. Ovarian cystic neoplasms can be benign, ...
The FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for the treatment of adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results